Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 15/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GSR | P00390 | 1/20 | 0.45 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9794246 | 0.92 | TXNRD1 (0.53) | TXNRD1LMNAGSRMAPTS1PR4 | |
| SCHEMBL2855541 | 0.87 | KCNH2 (0.47) | TXNRD1LMNAGSRMAPTNPSR1 | |
| SCHEMBL741498 | 0.87 | TXNRD1 (0.48) | TXNRD1LMNAGSRMAPTS1PR4 | |
| SCHEMBL9042043 | 0.87 | TXNRD1 (0.57) | TXNRD1LMNAGSRMAPTS1PR4 | |
| Hydrochloric Acid SCHEMBL10829567 | 0.86 | CHRM2 (0.46) | TXNRD1LMNAGSRMAPTNPSR1 | |
| SCHEMBL10654754 | 0.85 | TXNRD1 (0.55) | TXNRD1GSRMAPTS1PR4S1PR1 | |
| SCHEMBL9794390 | 0.84 | TXNRD1 (0.50) | TXNRD1GSRMAPTS1PR4S1PR1 | |
| SCHEMBL5832677 | 0.82 | TXNRD1 (0.63) | TXNRD1LMNAGSRGSTM2MAPT | |
| SCHEMBL28489675 | 0.82 | TXNRD1 (0.57) | TXNRD1GSRMAPTS1PR4S1PR1 | |
| SCHEMBL2860282 | 0.82 | NPSR1 (0.49) | TXNRD1GSRMAPTS1PR4S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254887-B9 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8349826-B2 | Oxazolidinone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-01-08 | — | — | US | disclosed |
| EP-2254887-B1 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-20100331308-A1 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-12-30 | — | — | US | disclosed |
| EP-2254887-A1 | OXAZOLIDINONE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009104159-A1 | OXAZOLIDINONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331308-A1 | OXAZOLIDINONE DERIVATIVES | OXA1L, UQCRB, O60361 | TXNRD1 2529/4885LMNA 1813/4885GSR 1120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.